They may also trigger the effector Th1 cells and CD8+ T cells, as well as favour the conversion of Th2 to Th1 in the secondary lymphoid tissues and tumour microenvironment, thus inhibiting cancer growth. This evidence concerns the gene CD8A and neoplasm.